Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Publications

ASCEND-Eye: Effects of Aspirin on Diabetic Retinopathy.

Sammons EL. et al, (2024), Ophthalmology, 131, 771 - 779

ASCEND-Eye: Effects of Omega-3 Fatty Acids on Diabetic Retinopathy.

Sammons EL. et al, (2024), Ophthalmology, 131, 526 - 533

Thromboxane biosynthesis and future events in diabetes: the ASCEND trial.

Petrucci G. et al, (2024), Eur Heart J, 45, 1355 - 1367

Thromboxane biosynthesis and risk of future events in diabetes mellitus: A sub-study of the ASCEND trial.

PARISH S. et al, (2023), European Heart Journal

ASCEND-Eye: Rationale, design and baseline characteristics for a sub-study of the ASCEND randomised trial, exploring the effects of aspirin and omega-3 fatty acids on diabetic retinopathy and age-related macular degeneration.

Sammons E. et al, (2023), Contemp Clin Trials Commun, 35

Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial.

Parish S. et al, (2022), Eur Heart J, 43, 2010 - 2019

Molecular Classification Improves Risk Assessment in Adult BCR-ABL1-negative B-ALL.

Paietta E. et al, (2021), Blood

Thromboxane metabolite excretion is associated with serious vascular events in diabetes mellitus: a sub-study of the ASCEND trial

Rocca B. et al, (2020), EUROPEAN HEART JOURNAL, 41, 2926 - 2926

At three years, patients with acute lymphoblastic leukaemia are still at risk for relapse. Results of the international MRC UKALLXII/ECOG E2993 trial.

Ganzel C. et al, (2020), Br J Haematol

Effects of Omega-3 Fatty Acid Supplements on Arrhythmias.

Parish S. et al, (2020), Circulation, 141, 331 - 333

Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.

ASCEND Study Collaborative Group None. et al, (2018), N Engl J Med, 379, 1529 - 1539

Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.

ASCEND Study Collaborative Group None. et al, (2018), N Engl J Med, 379, 1540 - 1550

Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features.

Godfrey AL. et al, (2018), J Clin Oncol

ASCEND: A Study of Cardiovascular Events iN Diabetes: Characteristics of a randomized trial of aspirin and of omega-3 fatty acid supplementation in 15,480 people with diabetes.

Bowman L. et al, (2018), Am Heart J, 198, 135 - 144

Prospective evaluation of quality of life in children treated in UKALL 2003 for acute lymphoblastic leukaemia: A cohort study.

Eiser C. et al, (2017), Pediatr Blood Cancer, 64

Once daily low-dose aspirin reduces urinary thromboxane B2 effectively even at 12-24 hours from dosing in the ASCEND (A Study of Cardiovascular Events iN Diabetes) trial

Aung T. et al, (2017), EUROPEAN HEART JOURNAL, 38, 426 - 426

Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII.

Kumar AJ. et al, (2016), Am J Hematol, 91, 1107 - 1112

in Philadelphia-Chromosome-Negative Acute Lymphoblastic Leukemia, Late Relapses Are Not Uncommon, Occur Mostly in Patients at Standard Risk and Have a Relatively Favorable Outcome. Results of the International ALL Trial: MRC Ukallxii/ECOG E2993

Ganzel C. et al, (2015), BLOOD, 126

High hyperdiploidy among adolescents and adults with acute lymphoblastic leukaemia (ALL): cytogenetic features, clinical characteristics and outcome.

Chilton L. et al, (2014), Leukemia, 28, 1511 - 1518

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.

Fielding AK. et al, (2014), Blood, 123, 843 - 850

Load More